Randomized Controlled Trial
doi: 10.1086/508493.
Epub 2006 Oct 6.
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma
Affiliations
- PMID: 17054068
- DOI: 10.1086/508493
Item in Clipboard
Randomized Controlled Trial
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma
J Infect Dis.
.
Abstract
In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 microg of the hemagglutinin (HA) of influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 microg of each HA, reactogenicity was minor. Among patients with similar prevaccination titers, 40% given 45 microg and 60% given 135 microg of rHAO developed an increase in influenza A/H3 neutralizing antibody levels; there were no increases in 4 given TIV. For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine.
Similar articles
-
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27. Vaccine. 2009. PMID: 19716456 Clinical Trial.
-
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.J Infect Dis. 2006 May 1;193(9):1223-8. doi: 10.1086/503050. Epub 2006 Mar 28. J Infect Dis. 2006. PMID: 16586358 Clinical Trial.
-
Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?Pediatrics. 2006 Sep;118(3):e570-8. doi: 10.1542/peds.2006-0198. Pediatrics. 2006. PMID: 16950948 Clinical Trial.
-
Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?J Infect Dis. 2008 Feb 15;197(4):490-502. doi: 10.1086/524146. J Infect Dis. 2008. PMID: 18275271 Review.
-
FluBlok, a recombinant hemagglutinin influenza vaccine.Influenza Other Respir Viruses. 2008 Nov;2(6):211-9. doi: 10.1111/j.1750-2659.2008.00053.x. Influenza Other Respir Viruses. 2008. PMID: 19453397 Free PMC article. Review.
Cited by
-
Practical review of immunizations in adult patients with cancer.Hum Vaccin Immunother. 2015;11(11):2606-14. doi: 10.1080/21645515.2015.1062189. Epub 2015 Jun 25. Hum Vaccin Immunother. 2015. PMID: 26110220 Free PMC article. Review.
-
Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.J Virol. 2010 Apr;84(7):3201-9. doi: 10.1128/JVI.02175-09. Epub 2010 Jan 13. J Virol. 2010. PMID: 20071572 Free PMC article.
-
Production of a novel influenza vaccine using insect cells: protection against drifted strains.Influenza Other Respir Viruses. 2007 Jan;1(1):35-40. doi: 10.1111/j.1750-2659.2006.00007.x. Influenza Other Respir Viruses. 2007. PMID: 19453478 Free PMC article. Review.
-
Influenza vaccination in cancer patients undergoing systemic therapy.Clin Med Insights Oncol. 2014 May 1;8:57-64. doi: 10.4137/CMO.S13774. eCollection 2014. Clin Med Insights Oncol. 2014. PMID: 24855405 Free PMC article. Review.
-
Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.Ther Adv Vaccines. 2015 Jul;3(4):97-108. doi: 10.1177/2051013615595595. Ther Adv Vaccines. 2015. PMID: 26478817 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
